TYK2 promotes malignant peripheral nerve sheath tumor progression through inhibition of cell death

Keyphrases

• B-cell Lymphoma 2 (Bcl-2) 8%
• Cancer Predisposition Syndrome 8%
• Cell Death 100%
• Cleaved caspase-3 8%
• Combined Modality Therapy 8%
• CRISPR-Cas9 System 8%
• Genomic Studies 8%
• Immunohistochemistry 8%
• Impaired Growth 8%
• Knockdown 16%
• Knockout Cells 8%
• Malignant Peripheral Nerve Sheath Tumor (MPNST) 100%
• Metastasis Model 8%
• Mutated Genes 8%
• Neurofibromatosis Type 1 (NF-1) 8%
• Neurofibromatosis Type I 8%
• Putative Drug Targets 8%
• Sarcoma 16%
• Short Hairpin RNA (shRNA) 8%
• Subcutaneous Model 8%
• Therapy Outcome 8%
• Tumor Cells 8%
• Tumor Pathogenesis 25%
• Tumor Progression 100%
• Tyrosine Kinase 2 (TYK2) 100%

Medicine and Dentistry

• Cancer Susceptibility 10%
• Cas9 10%
• Caspase 3 10%
• Cell Death 100%
• Clustered Regularly Interspaced Short Palindromic Repeat 10%
• Connective Tissue Cancer 20%
• Immunohistochemistry 10%
• In Vitro 10%
• Malignant Neoplasm 10%
• Malignant Peripheral Nerve Sheath Tumor 100%
• Metastatic Carcinoma 10%
• Neurofibromatosis Type I 10%
• Protein Tyrosine Kinase 100%
• Short Hairpin RNA 10%
• Tumor Cell 10%
• Tumor Progression 100%